Ability Biotherapeutics
PrivateLast Round
Seed
Jun 18, 2024
Total Funding Raised
$30M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Ability Biotherapeutics operates in Healthcare & Life Sciences and is based in Montreal. Its latest recorded funding round was a Seed round in June 2024.
Ability Biotherapeutics is a biotechnology company that develops logic-gated antibody therapeutics for cancer and autoimmune diseases using its proprietary AI-powered discovery platform, AbiLeap™.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ability Biotherapeutics Comparables
Compare Ability Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Synthetic Design Lab | 84% | |
| Tentarix Biotherapeutics | 81% | |
| LabGenius Therapeutics | 80% |
For institutional investors. Book with your work email.
Ability Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jun 18, 2024 | ||||
| Seed | Dec 6, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ability Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Investissement Québec | Seed |
| Amplitude Ventures | Seed |
| Investissement Québec | Seed |
| Fonds de solidarité FTQ | Seed |
| Alexandria Venture Investments | Seed |
| Seido Capital | Seed |
| Theodorus | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 12, 2026
Monthly visitors increased 41% MoM.
- Aug 20, 2026
Monthly visitors increased 55% MoM.
For institutional investors. Book with your work email.
Ability Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ability Biotherapeutics's valuation, stock price, and market status.
Is Ability Biotherapeutics a public or private company?
Ability Biotherapeutics is a private company.
What is the current stock price of Ability Biotherapeutics?
Ability Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Ability Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ability Biotherapeutics worth (valuation)?
Valuation information for Ability Biotherapeutics is not publicly available.
Can I buy Ability Biotherapeutics stock?
Ability Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ability Biotherapeutics's last funding round?
Ability Biotherapeutics's most recent funding round was Seed on June 18, 2024.
Who are the main investors in Ability Biotherapeutics?
Key investors in Ability Biotherapeutics include Amplitude Ventures.
Will Ability Biotherapeutics IPO soon?
No public IPO plans have been announced for Ability Biotherapeutics.
How can I track Ability Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Ability Biotherapeutics's shares on secondary markets.